68Ga-HER2 affibody + 18F-FDG + 18F-FES

This is a combination of three radiopharmaceutical imaging agents used in positron emission tomography (PET) for comprehensive molecular characterization of tumors, particularly in breast cancer and other solid tumors. **68Ga-HER2 affibody** is a radiolabeled small protein (affibody) that binds specifically to the human epidermal growth factor receptor 2 (HER2), enabling non-invasive assessment of HER2 expression across all tumor sites in the body. It provides high diagnostic accuracy for differentiating HER2-enriched cancers and can reveal heterogeneity between lesions[2][3][4][5]. **18F-FDG** (fluorodeoxyglucose) is a glucose analog labeled with fluorine-18, widely used as a PET tracer to assess metabolic activity, commonly reflecting tumor aggressiveness or viability. **18F-FES** (fluoroestradiol) is an estrogen analog labeled with fluorine-18 that binds to estrogen receptors, allowing visualization and quantification of estrogen receptor expression in tumors. The combination enables simultaneous evaluation of HER2 status, metabolic activity, and hormone receptor status within primary and metastatic lesions—supporting personalized treatment planning for breast cancer patients[5][7].

Other names

gallium-68 HER2 affibodygallium68 HER2 affibodygallium 68 HER2 affibodyfluorine-18 fluorodeoxyglucosefluorine18 fluorodeoxyglucosefluorine 18 fluorodeoxyglucosefluorine-18 fluoroestradiolfluorine18 fluoroestradiolfluorine 18 fluoroestradiol